MX2018005756A - Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas. - Google Patents
Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas.Info
- Publication number
- MX2018005756A MX2018005756A MX2018005756A MX2018005756A MX2018005756A MX 2018005756 A MX2018005756 A MX 2018005756A MX 2018005756 A MX2018005756 A MX 2018005756A MX 2018005756 A MX2018005756 A MX 2018005756A MX 2018005756 A MX2018005756 A MX 2018005756A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor
- fpr2
- lipoxin
- alx
- formyl
- Prior art date
Links
- 102100021126 N-formyl peptide receptor 2 Human genes 0.000 title abstract 6
- 101000818546 Homo sapiens N-formyl peptide receptor 2 Proteins 0.000 title abstract 4
- 101710109169 Formyl peptide receptor 2 Proteins 0.000 title abstract 2
- 101000931587 Mus musculus Formyl peptide receptor-related sequence 1 Proteins 0.000 title abstract 2
- 208000019622 heart disease Diseases 0.000 title abstract 2
- 101150103751 FPR2 gene Proteins 0.000 title 1
- 101100446655 Rhizopus delemar (strain RA 99-880 / ATCC MYA-4621 / FGSC 9543 / NRRL 43880) FKBP2 gene Proteins 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259498P | 2015-11-24 | 2015-11-24 | |
| PCT/US2016/063036 WO2017091496A1 (en) | 2015-11-24 | 2016-11-21 | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018005756A true MX2018005756A (es) | 2018-08-01 |
Family
ID=57544530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018005756A MX2018005756A (es) | 2015-11-24 | 2016-11-21 | Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180325869A1 (enExample) |
| EP (1) | EP3380091A1 (enExample) |
| JP (1) | JP2018538367A (enExample) |
| KR (1) | KR20180081528A (enExample) |
| CN (1) | CN108348479A (enExample) |
| AU (1) | AU2016359463A1 (enExample) |
| BR (1) | BR112018010155A8 (enExample) |
| CA (1) | CA3006291A1 (enExample) |
| EA (1) | EA201891007A1 (enExample) |
| IL (1) | IL259468A (enExample) |
| MX (1) | MX2018005756A (enExample) |
| SG (1) | SG11201803816RA (enExample) |
| WO (1) | WO2017091496A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102772801B1 (ko) | 2015-12-10 | 2025-02-24 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| ES2869129T3 (es) | 2017-06-09 | 2021-10-25 | Bristol Myers Squibb Co | Agonistas de piperidinona del receptor 2 de péptidos formilados |
| EP3634958B1 (en) * | 2017-06-09 | 2021-07-21 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| CN110996950B (zh) * | 2017-06-09 | 2023-04-04 | 百时美施贵宝公司 | 哌啶酮甲酰基肽2受体激动剂和甲酰基肽1受体激动剂 |
| KR102615099B1 (ko) | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| SG11202008504SA (en) | 2018-03-05 | 2020-10-29 | Bristol Myers Squibb Co | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| ES2964299T3 (es) | 2018-11-26 | 2024-04-05 | Bristol Myers Squibb Co | Derivados de pirrolidinona como agonistas del receptor del péptido formilado 2 |
| JP7700210B2 (ja) | 2020-07-09 | 2025-06-30 | ブリストル－マイヤーズ スクイブ カンパニー | ピラゾロンホルミルペプチド２受容体アゴニスト |
| JP7802765B2 (ja) | 2020-08-12 | 2026-01-20 | ブリストル－マイヤーズ スクイブ カンパニー | オキソピロリジン尿素ｆｐｒ２アゴニスト |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2225231T3 (da) * | 2007-12-18 | 2011-10-17 | Actelion Pharmaceuticals Ltd | Aminotriazolderivater som alx-agonister |
| CA2814826C (en) * | 2010-11-17 | 2019-02-12 | Actelion Pharmaceuticals Ltd | Bridged spiro[2.4]heptane ester derivatives |
| WO2013171687A1 (en) * | 2012-05-16 | 2013-11-21 | Actelion Pharmaceuticals Ltd | 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
| KR102772801B1 (ko) * | 2015-12-10 | 2025-02-24 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| SG11202008504SA (en) * | 2018-03-05 | 2020-10-29 | Bristol Myers Squibb Co | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
-
2016
- 2016-11-21 JP JP2018545568A patent/JP2018538367A/ja not_active Withdrawn
- 2016-11-21 SG SG11201803816RA patent/SG11201803816RA/en unknown
- 2016-11-21 US US15/776,927 patent/US20180325869A1/en not_active Abandoned
- 2016-11-21 AU AU2016359463A patent/AU2016359463A1/en not_active Abandoned
- 2016-11-21 WO PCT/US2016/063036 patent/WO2017091496A1/en not_active Ceased
- 2016-11-21 MX MX2018005756A patent/MX2018005756A/es unknown
- 2016-11-21 EA EA201891007A patent/EA201891007A1/ru unknown
- 2016-11-21 CN CN201680068442.7A patent/CN108348479A/zh active Pending
- 2016-11-21 CA CA3006291A patent/CA3006291A1/en not_active Abandoned
- 2016-11-21 KR KR1020187014477A patent/KR20180081528A/ko not_active Withdrawn
- 2016-11-21 EP EP16810536.9A patent/EP3380091A1/en not_active Withdrawn
- 2016-11-21 BR BR112018010155A patent/BR112018010155A8/pt not_active Application Discontinuation
-
2018
- 2018-05-17 IL IL259468A patent/IL259468A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201803816RA (en) | 2018-06-28 |
| CN108348479A (zh) | 2018-07-31 |
| IL259468A (en) | 2018-07-31 |
| AU2016359463A1 (en) | 2018-07-12 |
| KR20180081528A (ko) | 2018-07-16 |
| EA201891007A1 (ru) | 2018-11-30 |
| US20180325869A1 (en) | 2018-11-15 |
| BR112018010155A2 (pt) | 2018-11-21 |
| JP2018538367A (ja) | 2018-12-27 |
| WO2017091496A1 (en) | 2017-06-01 |
| BR112018010155A8 (pt) | 2019-02-26 |
| EP3380091A1 (en) | 2018-10-03 |
| CA3006291A1 (en) | 2017-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259468A (en) | The reference to formyl peptide receptor 2/lipoxin receptor 4a (fpr2/alx) for the treatment of heart disease | |
| PH12017500746B1 (en) | Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease | |
| PH12016501966A1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| WO2016037144A3 (en) | Cardiac pacing lead delivery system | |
| MX2016013049A (es) | Inhibidores de autotaxina espirociclicos sustituidos. | |
| EA201790180A1 (ru) | Способы и терапевтические комбинации для лечения опухолей | |
| MX2017005834A (es) | Polinucleotidos aad para el tratamiento de la enfermedad de parkinson. | |
| EP3180009A4 (en) | Zoledronic acid dosage forms for the treatment of pain | |
| PH12017500493A1 (en) | Combination therapy | |
| EA201790693A1 (ru) | Коррекция фигуры | |
| MX377438B (es) | Administracion de tasimelteon en condiciones de ayuno. | |
| ZA201800832B (en) | Metabolically robust analogs of cyp-eicosanoids for the treatment of cardiac disease | |
| MY195000A (en) | Method for the treatment of neurological disease | |
| EP3285771A4 (en) | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa | |
| IL274744A (en) | Phenoxy acids for the treatment of neuromuscular disorders | |
| SG11202112499VA (en) | Treatment of heart disease by disruption of the anchoring of pp2a | |
| IL253141B (en) | Products for administering medical or diagnostic preparations to the heart | |
| PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
| PL3710043T3 (pl) | Fgf10 do leczenia chorób serca | |
| GB201908180D0 (en) | Therapy for heart disorders | |
| HK40053333A (en) | Methods for treating parkinson's disease by administering resiniferatoxin | |
| HK40030261A (en) | Human microbiota derived n-acyl amides for the treatment of human disease | |
| AU2015902768A0 (en) | System for the Reduction of Adverse Effect on Human Tissue by Radiation | |
| MX2016010919A (es) | 4-bencilsulfonil-2-butenonitrilo. | |
| HK40025186A (en) | Methods for the treatment of leptomeningeal disease |